Patient photos

SOTYKTU Patient Photos

Review actual patient photos of moderate-to-severe plaque psoriasis treated with SOTYKTU outside pivotal clinical trials. Individual results may vary.

Patient 1

SCALP

Photos of a patient with moderate-to-severe plaque psoriasis treated with SOTYKTU in a non-registrational clinical trial (NCT05478499).9

Plaque Psoriasis on Scalp at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Scalp by Week 16 of Sotyktu Treatment

BY WEEK 16

Plaque Psoriasis on Scalp by Week 24 of Sotyktu Treatment

BY WEEK 24

Patient 2

LOWER LEG

HCP-submitted photos depict patient treated with SOTYKTU outside of clinical trials

Plaque Psoriasis on Lower Legs at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Lower Legs by Week 24 of Sotyktu Treatment

BY WEEK 24

Patient 4

LOWER LEG

HCP-submitted photos depict patient treated with SOTYKTU outside of clinical trials

Plaque Psoriasis on Lower Leg at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Lower Leg by Week 24 of Sotyktu Treatment

BY WEEK 24

Plaque Psoriasis on Lower Leg by Week 52 of Sotyktu Treatment

BY WEEK 52

Patient 2

ABDOMEN

HCP-submitted photos depict patient treated with SOTYKTU outside of clinical trials. Identifying characteristics have been obscured to protect patient privacy.

Plaque Psoriasis on Abdomen at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Abdomen by Week 24 of Sotyktu Treatment

BY WEEK 24

Patient 2

BACK

HCP-submitted photos depict patient treated with SOTYKTU outside of clinical trials. Identifying characteristics have been obscured to protect patient privacy.

Plaque Psoriasis on Back at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Back by Week 24 of Sotyktu Treatment

BY WEEK 24

Patient 3

PALM

Patient-submitted photos depict patient treated with SOTYKTU outside of clinical trials

Plaque Psoriasis on Palm at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Palm by Week 24 of Sotyktu Treatment

BY WEEK 24

Plaque Psoriasis on Palm by Week 52 of Sotyktu Treatment

BY WEEK 52

Patient 5

ELBOW

HCP-submitted photos depict patient treated with SOTYKTU outside of clinical trials

Plaque Psoriasis on Elbow at Baseline of Sotyktu treatment

BASELINE

Plaque Psoriasis on Elbow by Week 24 of Sotyktu Treatment

BY WEEK 24

ARE YOU READY TO EXPLORE MORE? SELECT A TOPIC BELOW.
References:
  1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  2. Data on file. BMS-REF-DEU-0020. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  3. Data on file. BMS-REF-DEU-0021. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  4. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40-51.
  5. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39.
  6. Data on file. BMS-REF-DEU-0075. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  7. Data on file. BMS-REF-DEU-0076. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  8. Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Poster presented at: Maui Derm for Dermatologists; January 24-28, 2022; Maui, HI.
  9. Data on File. BMS-REF-DEU-0148. Princeton, NJ: Bristol-Myers Squibb Company; 2024


SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
This site is intended for U.S. Healthcare Professionals only.
Otezla is a registered trademark of Amgen Inc.
© 2025 Bristol-Myers Squibb Company.
1787-US-2400641 11/24

1787-US-2400887 02/25